REGENXBIO Inc. filings document governance, operating results and material events for a biotechnology company developing AAV gene therapies. Recent 8-K disclosures include quarterly and annual results, FDA communications involving RGX-121 and RGX-111, and regulatory updates tied to a Biologics License Application and investigational new drug applications.
The filing record also covers collaboration and license matters, including an amendment to the AbbVie collaboration for surabgene lomparvovec and a settlement related to the GSK-REGENXBIO sublicense. Proxy materials describe board elections, stockholder meeting matters, executive compensation, equity awards and other governance disclosures for the Delaware corporation.
REGENXBIO Inc. announced changes to its board leadership. Kenneth T. Mills resigned from the board on October 14, 2026, effective October 21, 2026. The company said Mills recently became chief executive officer of another company and intends to focus his efforts on that role; his departure was not related to any disagreement with REGENXBIO on operations, policies or practices. In connection with Mills’s departure, the board appointed George Migausky as Chairman. Daniel Tassé stepped down as Lead Independent Director because the new Chairman is an independent director, and will remain a board member.
REGENXBIO Inc. (RGNX) is the issuer of the shares for which JPMorgan Chase & Co. reports beneficial ownership of 3,560,915 shares, or 5.3% of the class, as of September 30, 2026. JPMorgan reports sole voting power over 3,324,340 shares and sole dispositive power over 3,560,915 shares, with no shared voting or dispositive power.
On September 23, 2026, REGENXBIO Inc. entered into a settlement agreement with The Trustees of the University of Pennsylvania, Sarepta Therapeutics, Inc., Sarepta Therapeutics Three, LLC, and Catalent, Inc., concerning patent litigation related to Sarepta’s SRP-9001, also known as ELEVIDYS in the U.S. Sarepta will pay REGENXBIO $39.0 million within 10 days of the agreement’s effective date. Thereafter, the parties will terminate with prejudice all ongoing patent litigation regarding the patents in suit.
REGENXBIO and UPenn agreed to release current claims and not pursue specified future claims relating to Sarepta gene therapy products using an AAVrh74-based capsid, including ELEVIDYS. REGENXBIO also agreed not to sue over its patents covering ELEVIDYS in its existing form or the capsid sequence; that commitment does not extend to patents covering other aspects of gene therapy products.
REGENXBIO Inc. (RGNX) reported that Chief Technology Officer Craig Malzahn had 234 shares of common stock disposed of on September 1, 2026 to satisfy tax withholding obligations upon the vesting of previously granted restricted stock units. The shares were valued at $9.32 per share for this tax calculation, and Malzahn now directly holds 81,960 shares of REGENXBIO common stock.
REGENXBIO Inc. (RGNX) reported that Chief Financial Officer Mitchell Chan had 4,902 shares of common stock withheld on September 1, 2026 to pay tax liabilities arising from the vesting of restricted stock units originally granted on September 16, 2024. The shares were valued at $9.32 per share, based on the issuer’s closing price that day, and reflect a tax-withholding disposition rather than an open-market sale. Following this event, Chan directly holds 122,815 shares of REGENXBIO common stock. No Rule 10b5-1 trading plan is reported for this transaction.
REGENXBIO Inc. (RGNX) director Gregory Austin Ciongoli reported multiple equity transactions. He purchased 49,196 shares of common stock on August 26, 2026 at a weighted average price of $9.1411 per share in open-market trades, and 53,407 shares on August 27, 2026 at a weighted average price of $9.3560 per share in open-market trades.
On August 25, 2026, he also received an equity compensation package consisting of 15,432 shares of time-based restricted stock units that vest in three equal annual installments on August 25, 2027, 2028 and 2029, and a stock option for 69,609 shares of common stock at an exercise price of $8.91 per share, vesting one-third on August 25, 2027 and the remainder in equal monthly installments over the following 24 months.
REGENXBIO Inc. (RGNX) filed an initial insider ownership report (Form 3) for Gregory Austin Ciongoli, who is identified as a director of the company. The filing does not list any equity transactions or current holdings and includes a Power of Attorney as an exhibit.
REGENXBIO Inc. (RGNX) reported board and leadership changes along with related director compensation. The board elected Gregory (Greg) Ciongoli as an independent Class II director effective August 25, 2026, with his term running until the 2029 annual meeting. He was also appointed to the Audit Committee and the Nominating and Corporate Governance Committee.
Under the non-employee director compensation program, Mr. Ciongoli received an initial equity award with a grant date fair value of $550,000, split 75% into stock options and 25% into RSUs, with an exercise price of $8.91 per share and three-year vesting schedules, including full acceleration upon a change of control or death. He will receive a $45,000 annual board retainer plus $10,000 and $5,000 retainers for Audit and Nominating and Corporate Governance Committee service, respectively, and will be eligible for future annual equity awards.
The board accepted the resignations of directors Jean Bennett, M.D., Ph.D. and A.N. “Jerry” Karabelas, Ph.D., effective August 25, 2026. Both will serve as advisors to the company through February 2027, and the board size was reduced to nine directors.
REGENXBIO Inc. (RGNX) reported a significant regulatory setback for its RGX-121 gene therapy program for Mucopolysaccharidosis type II (Hunter Syndrome). The FDA has placed the Investigational New Drug application for the Phase I/II/III trial of RGX-121 on a clinical hold, and the company does not expect to resubmit the RGX-121 Biologics License Application in the near term.
The hold follows discovery of asymptomatic spine MRI findings (small nodules or cystic masses) in five CAMPSIITE® study participants dosed approximately three to six years ago. Investigators deemed these findings nonserious and radiologists believe they are likely benign, with patients showing stability to improvement on neurocognitive and neurobehavioral assessments. REGENXBIO states it remains focused on other late-stage programs, including RGX-202 for Duchenne muscular dystrophy and ABBV‑RGX‑314 for wet AMD and diabetic retinopathy, with upcoming regulatory and data milestones described as on track.